CA
CSTL icon

CastleArk Alternatives’s Castle Biosciences CSTL Stock Holding History

CastleArk Alternatives’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-147,867
Closed -$9.83M – 78
2021
Q3 		$9.83M Buy
+147,867
New +$10.4M 0.38% 76

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

CastleArk Alternatives's CSTL Position: Q4 2021 in Review

CastleArk Alternatives sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 147,867 shares — an estimated $9.83M sold.

CastleArk Alternatives first reported a position in CSTL in Q3 2021 and held it in 1 quarter. The position peaked at $9.83M in Q3 2021. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • CastleArk Alternatives reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 147,867 Castle Biosciences shares in Q4 2021, an estimated $9.83M.
  • CastleArk Alternatives first reported a position in Castle Biosciences in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Castle Biosciences position peaked at $9.83M in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.